Jacqueline M. Lafky

2.8k total citations
60 papers, 2.0k citations indexed

About

Jacqueline M. Lafky is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Jacqueline M. Lafky has authored 60 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Cancer Research. Recurrent topics in Jacqueline M. Lafky's work include HER2/EGFR in Cancer Research (16 papers), Cancer Treatment and Pharmacology (16 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Jacqueline M. Lafky is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Cancer Treatment and Pharmacology (16 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Jacqueline M. Lafky collaborates with scholars based in United States, Puerto Rico and Switzerland. Jacqueline M. Lafky's co-authors include Nita J. Maihle, Andre T. Baron, Charles L. Loprinzi, Kathryn J. Ruddy, Rui Qin, Jason A. Wilken, Karl C. Podratz, Deirdre R. Pachman, Cecelia H. Boardman and Drew K. Seisler and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jacqueline M. Lafky

58 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacqueline M. Lafky United States	24	1.1k	385	322	303	251	60	2.0k
Jean-Louis Misset France	22	1.6k 1.5×	446 1.2×	210 0.7×	314 1.0×	513 2.0×	42	2.5k
Daniel A. Nikcevich United States	24	1.3k 1.2×	437 1.1×	293 0.9×	169 0.6×	449 1.8×	72	2.3k
Luigi Celio Italy	22	1.2k 1.1×	244 0.6×	218 0.7×	547 1.8×	351 1.4×	82	2.2k
Christophe Leux France	24	480 0.4×	259 0.7×	203 0.6×	280 0.9×	340 1.4×	57	1.7k
Gamini S. Soori United States	23	1.6k 1.4×	428 1.1×	395 1.2×	332 1.1×	642 2.6×	70	2.6k
Halle C. F. Moore United States	22	1.0k 0.9×	202 0.5×	107 0.3×	118 0.4×	415 1.7×	88	1.6k
Klaus Baumann Germany	22	1.0k 0.9×	378 1.0×	117 0.4×	319 1.1×	421 1.7×	84	2.2k
Marina Elena Cazzaniga Italy	28	2.1k 1.9×	540 1.4×	217 0.7×	316 1.0×	639 2.5×	138	3.2k
Αngelos Koutras Greece	28	1.6k 1.4×	588 1.5×	156 0.5×	175 0.6×	543 2.2×	132	2.5k
Naoko Honma Japan	26	603 0.5×	520 1.4×	426 1.3×	422 1.4×	342 1.4×	88	2.0k

Countries citing papers authored by Jacqueline M. Lafky

Since Specialization

Citations

This map shows the geographic impact of Jacqueline M. Lafky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline M. Lafky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline M. Lafky more than expected).

Fields of papers citing papers by Jacqueline M. Lafky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline M. Lafky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline M. Lafky. The network helps show where Jacqueline M. Lafky may publish in the future.

Co-authorship network of co-authors of Jacqueline M. Lafky

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline M. Lafky. A scholar is included among the top collaborators of Jacqueline M. Lafky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline M. Lafky. Jacqueline M. Lafky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenberg, Shoshana M., Jun He, Jacqueline M. Lafky, et al.. (2023). Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. 130(5). 750–769. 2 indexed citations

Tawfik, Bernard, Zoneddy Dayao, Ursa Brown‐Glaberman, et al.. (2023). A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2. Supportive Care in Cancer. 31(11). 637–637. 7 indexed citations

Guerard, Emily J., Jennifer Le‐Rademacher, Margaret Kemeny, et al.. (2021). Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603). JCO Clinical Cancer Informatics. 5(5). 435–441. 9 indexed citations

Guerard, Emily J., et al.. (2021). How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902). JCO Clinical Cancer Informatics. 5(5). 442–449. 4 indexed citations

Cathcart-Rake, Elizabeth, Paul J. Novotny, Roberto A. Leon‐Ferre, et al.. (2020). A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Supportive Care in Cancer. 29(1). 387–396. 11 indexed citations

Li, Daneng, Linda McCall, Olwen Hahn, et al.. (2018). Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research and Treatment. 171(2). 325–334. 2 indexed citations

Foster, Jared C., Drew K. Seisler, Jacqueline M. Lafky, et al.. (2018). Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of Geriatric Oncology. 9(4). 321–328. 4 indexed citations

Freedman, Rachel A., Travis Dockter, Jacqueline M. Lafky, et al.. (2018). Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602). The Oncologist. 23(9). 1016–1023. 31 indexed citations

Hopkins, Judith O., Jake Allred, Arti Hurria, et al.. (2017). Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research and Treatment. 166(3). 793–808. 9 indexed citations

10.

Foster, Jared C., Jennifer Le‐Rademacher, Josephine Feliciano, et al.. (2017). Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: Observations from a 446‐patient cohort. Cancer. 123(21). 4193–4198. 5 indexed citations

11.

Foster, Jared C., Drew K. Seisler, Jacqueline M. Lafky, et al.. (2016). Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). Blood. 128(22). 536–536.

12.

Pachman, Deirdre R., Rui Qin, Drew K. Seisler, et al.. (2016). Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Supportive Care in Cancer. 24(12). 5059–5068. 65 indexed citations

13.

Majithia, Neil, Philip J. Atherton, Jacqueline M. Lafky, et al.. (2015). Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Supportive Care in Cancer. 24(3). 1219–1226. 11 indexed citations

14.

Jatoi, Aminah, Hyman B. Muss, Jake Allred, et al.. (2015). Social support and its implications in older, early‐stage breast cancer patients in CALGB 49907 (Alliance A171301). Psycho-Oncology. 25(4). 441–446. 17 indexed citations

15.

Moreno‐Aspitia, Alvaro, David W. Hillman, Kathleen Tenner, et al.. (2013). Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 119(15). 2675–2682. 40 indexed citations

16.

Lafky, Jacqueline M., Jason A. Wilken, Andre T. Baron, & Nita J. Maihle. (2008). Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1785(2). 232–265. 178 indexed citations

17.

Lafky, Jacqueline M., Andre T. Baron, & Nita J. Maihle. (2006). Soluble Epidermal Growth Factor Receptor Acridinium-Linked Immunosorbent Assay. Humana Press eBooks. 327. 39–48. 1 indexed citations

18.

Baron, Andre T., Elsa M. Cora, Jacqueline M. Lafky, et al.. (2003). Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.. PubMed. 12(2). 103–13. 82 indexed citations

19.

Baron, Andre T., Jacqueline M. Lafky, Cecelia H. Boardman, et al.. (1999). Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.. PubMed. 8(2). 129–37. 62 indexed citations

20.

Baron, Andre T., Jacqueline M. Lafky, Denise C. Connolly, et al.. (1998). A sandwich type Acridinium-Linked ImmunoSorbent Assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. Journal of Immunological Methods. 219(1-2). 23–43. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact